In the original publication [1], the Conflicts of Interest statement was inaccurate. The correct Conflicts of Interest is as follows:
Conflicts of Interest: Yuki Taya, Mari Mizunaga, Shunsuke Nakao, and Yukihiro Nomura are employees of Japan Tobacco, Inc. Yuki Taya is also affiliated with Tohoku University for degree purposes. The authors declare that this study received funding from Akros Pharma, Inc., Princeton, NJ, USA. Akros Pharma, Inc. is a subsidiary of Japan Tobacco, Inc. Japan Tobacco, Inc. provided financial support for the conduct of the study. However, Japan Tobacco, Inc. was not involved in the study design, data collection, analysis, interpretation, writing of the manuscript, or the decision to submit it for publication.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Reference
- 1.Taya Y., Mizunaga M., Nakao S., Jutanom M., Shimizu N., Nomura Y., Nakagawa K. Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity. Molecules. 2023;28:1576. doi: 10.3390/molecules28041576. [DOI] [PMC free article] [PubMed] [Google Scholar]